Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis

Open access
Sahoo, D.H., Bandyopadhyay, D., Xu, M., Pearson, K., Parambil, J.G., Lazar, C.A., Chapman, J.T., Culver, D.A.·2011·European Respiratory Journal

Abstract

Leflunomide has been reported as an alternative therapy in sarcoidosis. However, the published data are limited. We performed a retrospective chart review of the tolerance and effects of leflunomide therapy in patients with sarcoidosis. 76 patients were included. The most common reasons for initiation were progression of disease or failure of other immunomodulator therapy. Side-effects attributable to leflunomide were noted in 34% of subjects, prompting discontinuation in 17%. The lungs were a target of therapy in 33 (44%) and extrapulmonary organs were a target in 45 (59%). The mean± sd change in forced vital capacity in the 6 months prior to leflunomide was −0.1±0.3 L, and it was +0.09±0.3 L in the following 6 months (p=0.01). For extrapulmonary target organ response, 51% had a good response and 32% a partial response. The median corticosteroid dose at initiation was 10 mg (interquartile range 5–20) mg at baseline, and 0 (0–10) mg at the 6-month follow-up (p<0.001). Leflunomide is a viable alternative agent for pulmonary and extrapulmonary sarcoidosis. Leflunomide appears to facilitate reduction of steroid dose and can be considered as monotherapy or as add-on therapy in cases of progressive disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00195010

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. 10.1074/jbc.273.34.21682 · DOI · Paper page
  2. Cohen, 2003, Leflunomide, Int J Clin Pract, 57, 115, 10.1111/j.1742-1241.2003.tb10439.x · doi:10.1111/j.1742-1241.2003.tb10439.x
  3. 10.2165/00063030-199912040-00007 · DOI
  4. 10.3949/ccjm.71.2.88 · DOI
  5. 10.1164/ajrccm.160.2.ats4-99 · DOI · Paper page
  6. Baughman, 2004, Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 21, 43
  7. Judson, 1999, Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 16, 75
  8. 10.1378/chest.130.1.30 · doi:10.1378/chest.130.1.30
  9. Stoller, 1993, Trial of standard versus modified expiration to achieve end-of-test spirometry criteria, Am Rev Respir Dis, 148, 275, 10.1164/ajrccm/148.2.275 · DOI
  10. 10.1016/j.ccm.2008.03.012 · DOI · Paper page
  11. 10.1055/s-0030-1262218 · doi:10.1055/s-0030-1262218
  12. Sweiss, 2010, Sarcoidosis requiring systemic steroid: why not a steroid-sparing regimen up-front?, Sarcoidosis Vasc Diffuse Lung Dis, 27, 3
  13. Baughman, 2000, Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial, Sarcoidosis Vasc Diffuse Lung Dis, 17, 60
  14. 10.1378/chest.125.3.997 · DOI · Paper page
  15. 10.1016/j.rmed.2009.12.009 · DOI · Paper page
  16. 10.1093/rheumatology/keg156 · doi:10.1093/rheumatology/keg156
  17. Pinto, 2006, Leflunomide in clinical practice, Acta Reumatol Port, 31, 215
  18. 10.1111/j.1445-5994.2008.01792.x · doi:10.1111/j.1445-5994.2008.01792.x
  19. 10.2165/11532390-000000000-00000 · doi:10.2165/11532390-000000000-00000
  20. 10.1136/ard.61.1.42 · doi:10.1136/ard.61.1.42
  21. Bettembourg-Brault, 2006, Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs, Clin Exp Rheumatol, 24, 168
  22. 10.1007/s10067-010-1425-3 · DOI
  23. 10.2169/internalmedicine.45.1455 · doi:10.2169/internalmedicine.45.1455
  24. 10.1093/rheumatology/kep052 · doi:10.1093/rheumatology/kep052
  25. 10.2165/11316650-000000000-00000 · DOI

Cited by

See all 173

Metadata

Authors
Sahoo, D. H., Bandyopadhyay, D., Xu, M., Pearson, K., Parambil, J. G., Lazar, C. A., Chapman, J. T., & Culver, D. A.
Venue
European Respiratory Journal
Published
2011-05-12
Volume
38
Issue
5
Pages
1145-1150
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2104680378
Cited by
173
References
0
FWCI
6.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. https://app.cochat.ai/papers/10.1183/09031936.00195010
The paper
Sahoo, D. H., Bandyopadhyay, D., Xu, M., Pearson, K., Parambil, J. G., Lazar, C. A., Chapman, J. T., & Culver, D. A. (2011). Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. European Respiratory Journal. https://doi.org/10.1183/09031936.00195010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.